Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Investigational Thiophene Drug Kills Tuberculosis Bacteria by Blocking Mycolic Acid Synthesis

By BiotechDaily International staff writers
Posted on 02 Jul 2013
An experimental drug prevents growth of the tuberculosis (TB)-causing bacterium, Mycobacterium tuberculosis (Mtb), by blocking the metabolic pathway for synthesis of mycolic acid, which is an essential component of the organism's cell membrane.

The cell envelope of M. tuberculosis is distinctive and is associated with its pathogenicity. Features that are very prominent in the cell envelope are the presence of arabinogalactan-mycolate covalently linked to the cell wall peptidoglycan via a phosphodiester bond located on the inner leaflet of the outer membrane and of a free glycolipid called trehalose dimycolate (TDM), which accumulates in a cord-like fashion on the surface of the cells. This provides a thick layer of lipid on the outer part of the cell and protects the tubercle bacillus from noxious chemicals and the host's immune system. Mycolic acids are the major constituents of this protective layer. They also play other important roles as structural components of the cell wall and envelope. More specifically, the cyclopropane rings in mycolic acids of Mtb contribute to the structural integrity of the cell wall complex and protect the bacillus from oxidative stress (hydrogen peroxide).
Investigators at the University of Medicine and Dentistry of New Jersey (Newark, USA) described a new class of thiophene compounds that killed Mtb by the previously uncharacterized mechanism of Pks13 (polyketide synthase 13) inhibition. The Pks13 enzyme catalyzes the condensation of two fatty acyl chains in the final steps of mycolic acid biosynthesis. Thiophenes are important heterocyclic compounds that are widely employed as building blocks in many agriculture and pharmaceuticals chemicals.

Results reported in the June 16, 2013, online edition of the journal Nature Chemical Biology revealed that treatment of Mtb cultures with an experimental thiophene drug was bactericidal and equivalent to treatment with the first-line drug isoniazid, but was less likely to permit emergent resistance. Combined isoniazid and thiophene treatment resulted in complete inhibition of Mtb growth.

“Mtb is a little ball of soap,” said senior author Dr. David Alland, professor of medicine at the University of Medicine and Dentistry of New Jersey. “This study confirms that M. tuberculosis Pks13 is required for mycolic acid biosynthesis, validates it as a druggable target, and demonstrates the therapeutic potential of simultaneously inhibiting multiple targets in the same biosynthetic pathway.”

Related Links:

University of Medicine and Dentistry of New Jersey



Channels

Genomics/Proteomics

view channel
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).

Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.